Nabriva Therapeutics AG, a Vienna, Austria- and Philadelphia, PA-based biotechnology company focused on developing pleuromutilins, a new class of antibiotics for the treatment of serious infections caused by resistant gram-positive and gram-negative bacteria, completed a $120m Series B financing.
The round was led by new US based investors Vivo Capital and OrbiMed, with participation from EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. In conjunction with the funding, representatives of Vivo Capital and OrbiMed will be joining the Nabriva Supervisory Board.
The initial tranche of $50m will enable the company to advance its lead product, lefamulin, into clinical phase 3 studies in community-acquired bacterial pneumonia (CABP) and to continue the development of its product pipeline.
Led by Dr Colin Broom, Chief Executive Officer, Nabriva is focused on the discovery and development of pleuromutilin antibiotics. Its lead product, lefamulin (BC‑3781), is the first systemically available pleuromutilin for human use and is entering pivotal phase 3 studies for the treatment of community-acquired bacterial pneumonia (CABP). Lefamulin possesses in vitro activity against the most common pathogens associated with CABP, specifically S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, M. pneumoniae, L. pneumophila, and C. pneumoniae, including multi-drug resistant strains.
Preclinical programs include the Extended Spectrum Pleuromutilins (ESPs), a new generation of antibacterials possessing in vitro activity against urgent and serious bacterial threats identified by the Centers for Disease Control and Prevention (CDC) including carbapenem-resistant Enterobacteriaceae (CRE), while maintaining the antimicrobial spectrum of lefamulin.